Shandong Buchang Pharmaceuticals Co., Ltd. and Shandong Buchang Shenzhou Pharmaceutical Co., Ltd signed Cooperation Framework Agreement to acquire Beijing Chengrui Technology Co., Ltd. from Beijing Longle Zhixin Group Co., Ltd and Xu Shanshan for approximately CNY 270 million.
October 16, 2021
Share
Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) and Shandong Buchang Shenzhou Pharmaceutical Co., Ltd signed Cooperation Framework Agreement to acquire Beijing Chengrui Technology Co., Ltd. from Beijing Longle Zhixin Group Co., Ltd and Xu Shanshan for approximately CNY 270 million on October 16, 2021. As of October 10, 2021, The transaction received approval from the acquirer board. As of November 3, 2021, Beijing Chengrui obtained the business license issued by the Market Supervision Administration of Chaoyang District Beijing City recently.
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
Shandong Buchang Pharmaceuticals Co., Ltd. and Shandong Buchang Shenzhou Pharmaceutical Co., Ltd signed Cooperation Framework Agreement to acquire Beijing Chengrui Technology Co., Ltd. from Beijing Longle Zhixin Group Co., Ltd and Xu Shanshan for approximately CNY 270 million.